Rasagiline is a selective and potent drug used for the treatment of Parkinson's disease. The first crystal structure of a salt of rasagiline, the title compound, bis[(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-aminium] ethanedisulfonate, 2C(12)H(14)N(+).C(2)H(4)O(6)S(2)(-), was determined from crystals grown by gas diffusion. The compound has monoclinic (C2) symmetry. The ethane group of the ethanedisulfonate anion is disordered over three positions. The C(2)-symmetric ethanedisulfonate anions are connected by four N-H...O hydrogen bonds to four rasagiline cations. This leads to large 18-membered rings which are arranged in ladders in the [010] direction. The extended hydrogen-bonding architecture may explain the stability of the structure. Rasagiline ethanedisulfonate is nonhygroscopic. During a polymorph screen, no hydrates, solvates or polymorphs were found.